A potential new therapeutic approach for Friedreich ataxia: Induction of frataxin expression with TALE proteins

Molecular Therapy Nucleic Acids

Volumn 2, Issue SEP, 2013, Pages e119-

  Chapdelaine, Pierre ^a,b   Coulombe, Zoé ^a,b   Chikh, Amina ^a,b   Gérard, Catherine ^a,b   Tremblay, Jacques P ^a,b  

^a University Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Frataxin; Friedreich ataxia; Gene expression; TAL effector; Transcription factor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; FRATAXIN; MESSENGER RNA; MYOD PROTEIN; RECOMBINANT PROTEIN; SERUM RESPONSE FACTOR; SYNAPTOTAGMIN I; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2 ALPHA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; FIBROBLAST; FRIEDREICH ATAXIA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84899750944     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.41     Document Type: Article

References (43)

1. Boch, J, Scholze, H, Schornack, S, Landgraf, A, Hahn, S, Kay, S et al. (2009). Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326: 1509-1512.
2. Moscou, MJ and Bogdanove, AJ (2009). A simple cipher governs DNA recognition by TAL effectors. Science 326: 1501.
3. Cermak, T, Doyle, EL, Christian, M, Wang, L, Zhang, Y, Schmidt, C et al. (2011). Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 39: e82.
4. Reyon, D, Tsai, SQ, Khayter, C, Foden, JA, Sander, JD and Joung, JK (2012). FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 30: 460-465.
5. Sanjana, NE, Cong, L, Zhou, Y, Cunniff, MM, Feng, G and Zhang, F (2012). A transcription activator-like effector toolbox for genome engineering. Nat Protoc 7: 171-192.
6. Zhang, F, Cong, L, Lodato, S, Kosuri, S, Church, GM and Arlotta, P (2011). Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 29: 149-153.
7. Garg, A, Lohmueller, JJ, Silver, PA and Armel, TZ (2012). Engineering synthetic TAL effectors with orthogonal target sites. Nucleic Acids Res 40: 7584-7595.
8. Campuzano, V, Montermini, L, Moltò, MD, Pianese, L, Cossée, M, Cavalcanti, F et al. (1996). Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271: 1423-1427. (Pubitemid 26089479)
9. Pandolfo, M (2006). Iron and Friedreich ataxia. J Neural Transm Suppl: 143-146.
10. Pandolfo, M (2012). Friedreich ataxia. Handb Clin Neurol 103: 275-294.
11. Becker, E and Richardson, DR (2001). Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int J Biochem Cell Biol 33: 1-10. (Pubitemid 32146462)
12. Wallis, J, Shaw, J, Wilkes, D, Farrall, M, Williamson, R, Chamberlain, S et al. (1989). Prenatal diagnosis of Friedreich ataxia. Am J Med Genet 34: 458-461. (Pubitemid 19284638)
13. Rötig, A, de Lonlay, P, Chretien, D, Foury, F, Koenig, M, Sidi, D et al. (1997). Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17: 215-217.
14. Babady, NE, Carelle, N, Wells, RD, Rouault, TA, Hirano, M, Lynch, DR et al. (2007). Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments. Mol Genet Metab 92: 23-35. (Pubitemid 47361887)
15. Cooper, JM and Schapira, AH (2003). Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy. Biofactors 18: 163-171. (Pubitemid 38030711)
16. Harding, AE (1981). Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104: 589-620.
17. Lynch, DR, Farmer, JM, Balcer, LJ and Wilson, RB (2002). Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 59: 743-747. (Pubitemid 34517755)
18. Pandolfo, M (1999). Molecular pathogenesis of Friedreich ataxia. Arch Neurol 56: 1201-1208.
19. Singh, G, Binstadt, BA, Black, DF, Corr, AP and Rummans, TA (2001). Electroconvulsive therapy and Friedreich's ataxia. J ECT 17: 53-54. (Pubitemid 32246867)
20. Tremblay, JP, Chapdelaine, P, Coulombe, Z and Rousseau, J (2012). Transcription activator-like effector proteins induce the expression of the frataxin gene. Hum Gene Ther 23: 883-890.
21. Kim, E, Napierala, M and Dent, SY (2011). Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxia. Nucleic Acids Res 39: 8366-8377.
22. Costa, FC, Fedosyuk, H, Neades, R, de Los Rios, JB, Barbas, CF 3rd and Peterson, KR (2012). Induction of fetal hemoglobin in vivo mediated by a synthetic γ-globin zinc finger activator. Anemia 2012: 507894.
23. Magnenat, L, Schwimmer, LJ and Barbas, CF 3rd (2008). Drug-inducible and simultaneous regulation of endogenous genes by single-chain nuclear receptor-based zinc-finger transcription factor gene switches. Gene Ther 15: 1223-1232.
24. Beltran, AS, Sun, X, Lizardi, PM and Blancafort, P (2008). Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther 7: 1080-1090.
25. Shieh, JC, Cheng, YC, Su, MC, Moore, M, Choo, Y and Klug, A (2007). Tailor-made zinc-finger transcription factors activate FLO11 gene expression with phenotypic consequences in the yeast Saccharomyces cerevisiae. PLoS ONE 2: e746.
26. Beltran, A, Parikh, S, Liu, Y, Cuevas, BD, Johnson, GL, Futscher, BW et al. (2007). Reactivation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 26: 2791-2798. (Pubitemid 46663828)
27. Lund, CV, Blancafort, P, Popkov, M and Barbas, CF 3rd (2004). Promoter-targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation. J Mol Biol 340: 599-613. (Pubitemid 38798003)
28. Al-Mahdawi, S, Pinto, RM, Varshney, D, Lawrence, L, Lowrie, MB, Hughes, S et al. (2006). GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 88: 580-590. (Pubitemid 44540244)
29. Al-Mahdawi, S, Pinto, RM, Ismail, O, Varshney, D, Lymperi, S, Sandi, C et al. (2008). The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 17: 735-746. (Pubitemid 351292262)
30. Pook, MA, Al-Mahdawi, S, Carroll, CJ, Cossée, M, Puccio, H, Lawrence, L et al. (2001). Rescue of the Friedreich's ataxia knockout mouse by human YAC transgenesis. Neurogenetics 3: 185-193. (Pubitemid 33738404)
31. Morbitzer, R, Römer, P, Boch, J and Lahaye, T (2010). Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors. Proc Natl Acad Sci USA 107: 21617-21622.
32. Römer, P, Recht, S, Strauss, T, Elsaesser, J, Schornack, S, Boch, J et al. (2010). Promoter elements of rice susceptibility genes are bound and activated by specific TAL effectors from the bacterial blight pathogen, Xanthomonas oryzae pv. oryzae. New Phytol 187: 1048-1057.
33. Li, L, Piatek, MJ, Atef, A, Piatek, A, Wibowo, A, Fang, X et al. (2012). Rapid and highly efficient construction of TALE-based transcriptional regulators and nucleases for genome modification. Plant Mol Biol 78: 407-416.
34. Sandi, C, Al-Mahdawi, S and Pook, MA (2013). Epigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy. Genet Res Int 2013: 852080.
35. Pandolfo, M (2012). Friedreich ataxia: new pathways. J Child Neurol 27: 1204-1211.
36. Schwarze, SR, Ho, A, Vocero-Akbani, A and Dowdy, SF (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572. (Pubitemid 29420581)
37. Morris, MC, Depollier, J, Mery, J, Heitz, F and Divita, G (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19: 1173-1176. (Pubitemid 33115705)
38. Noguchi, H, Matsushita, M, Kobayashi, N, Levy, MF and Matsumoto, S (2010). Recent advances in protein transduction technology. Cell Transplant 19: 649-654.
39. Münst, B, Patsch, C and Edenhofer, F (2009). Engineering cell-permeable protein. J Vis Exp: pii: 1627.
40. Chapdelaine, P, Kang, J, Boucher-Kovalik, S, Caron, N, Tremblay, JP and Fortier, MA (2006). Decidualization and maintenance of a functional prostaglandin system in human endometrial cell lines following transformation with SV40 large T antigen. Mol Hum Reprod 12: 309-319. (Pubitemid 43821794)
41. Bultmann, S, Morbitzer, R, Schmidt, CS, Thanisch, K, Spada, F, Elsaesser, J et al. (2012). Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALES and inhibition of epigenetic modifiers. Nucleic Acids Res 40: 5368-5377.
42. Luu-The, V, Paquet, N, Calvo, E and Cumps, J (2005). Improved real-time RT-PCR method for high-throughput measurements using second derivative calculation and double correction. BioTechnigues 38: 287-293. (Pubitemid 40216386)
43. Chapdelaine, P, Vignola, K and Fortier, MA (2001). Protein estimation directly from SDS-PAGE loading buffer for standardization of samples from cell lysates or tissue homogenates before Western blot analysis. BioTechnigues 31: 478, 480, 482.